

POSTER PRESENTATION

Open Access

Incident vertebral fractures 12 months following glucocorticoid initiation in children with rheumatic disorders

Bianca A Lang^{1*}, Celia Rodd², Timothy Ramsay¹⁰, David A Cabral⁷, Peter B Dent³, Janet E Ellsworth⁶, Kristin M Houghton⁷, Adam Huber¹, Roman Jurencak¹⁰, Maggie Larché³, Claire MA LeBlanc⁶, Brian Lentle⁷, MaryAnn Matzinger¹⁰, Paivi M Miettunen⁸, Kiem Oen⁹, Johannes Roth¹⁰, Claire Saint-Cyr⁵, Rosie Scuccimarri², Nazih Shenouda¹⁰, Leanne M Ward¹⁰, Canadian STOPP Consortium⁴

From 2011 Pediatric Rheumatology Symposium sponsored by the American College of Rheumatology Miami, FL, USA. 2-5 June 2011

Purpose

Compromised bone health is recognized as an important source of morbidity among children with glucocorticoid (GC)-treated rheumatic diseases (RD). The aims of this study were to determine the frequency and characteristics of incident vertebral fractures (VF) 12 months after GC initiation in a prospectively-followed cohort of children with RD, and to examine clinical factors associated with their development.

Methods

Children (< 17 years) initiating GC for treatment of RD between January 2005 and December 2007 in ten participating Canadian tertiary pediatric centers were enrolled in the Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) study. Enrolled patients had baseline (within 30 days of initiating GC) and 6- monthly spine areal (a) BMD studies. Additionally, radiographs of the thoracolumbar spine at baseline and 12 months (m) were evaluated using the Genant semi-quantitative method. Fractures present at baseline (prevalent VFs) were documented. An incident VF was defined as a new VF or worsening of an existing fracture. Patients also had baseline and 3 monthly assessment of GC exposure, clinical status including disease activity (measured on a 10 cm visual analogue scale by the patient's rheumatologist), and questionnaires to determine physical activity and vitamin D/ calcium intake.

Results

Of 135 patients enrolled, data were available on 118 (64% female, median age 10.8 years) at 12 m. Diagnoses included juvenile dermatomyositis (JDM) (23%), juvenile idiopathic arthritis (JIA) (36 %), systemic lupus (SLE) and related conditions (18%), systemic vasculitis (14%), and other (9%). At 12 m, 7 patients (6%) had 12 incident VFs (3 SLE, 2 JDM, 1 vasculitis, 1 overlap). All incident VFs were new fractures; 5 patients had a single VF, one had 2 VFs and one had 5 VFs. Three patients had mild and 4 had moderate VFs. Nine (75%) of the incident VFs were thoracic and 11 (92%) had wedge morphology. Patients with and without incident VFs were similar for age, gender, pubertal status, disease activity, physical activity, vitamin D/calcium intake and presence of back pain. The decrease in spine aBMD and increase in BMI in the first 6 months was larger in those with incident VFs (Δ spine aBMD Z-score mean -0.8, SD 0.4; Δ BMI Z-score +1.7, SD 1.0) versus those without (Δ spine aBMD Z-score -0.4, SD 0.5; \triangle BMI Z-score +0.5 SD 0.8). Cumulative GC dose (g/m²) was almost double in those with incident VFs (median 9.3 g/m², range 3.0-12.5) versus those without (median 5.4, range 0.01-27.5); with the greatest difference in GC dose seen within the first 6m. None of the 9 children with baseline prevalent VFs had incident fractures. In 8 of these 9 patients, spine status had improved overall at 12 m.

Conclusion

Incident VFs occurred in a small proportion of our cohort (6%); however one patient was more severely

¹Dalhousie University, Halifax, NS, Canada Full list of author information is available at the end of the article



affected. Children with incident VFs received almost twice as much GC therapy as those without, had a greater decline in spine BMD, and manifested greater increases in BMI. Back pain and baseline prevalent VFs did not appear to be associated with incident VFs. Funded by CIHR.

Disclosure

Bianca A. Lang: None; Celia Rodd: None; Timothy Ramsay: None; David A. Cabral: None; Peter B. Dent: Roche, 6; Janet E. Ellsworth: None; Kristin M. Houghton: None; Adam Huber: None; Roman Jurencak: None; Maggie Larché: None; Claire M.A. LeBlanc: None; Brian Lentle: None; MaryAnn Matzinger: None; Paivi M. Miettunen: None; Kiem Oen: None; Johannes Roth: None; Claire Saint-Cyr: None; Rosie Scuccimarri: None; Nazih Shenouda: None; Leanne M. Ward: None; and the Canadian STOPP Consortium: None.

Author details

¹Dalhousie University, Halifax, NS, Canada. ²McGill University, Montreal, QC, Canada. ³McMaster University, Hamilton, ON, Canada. ⁴National Pediatric Bone Health Working Group, Ottawa, ON, Canada. ⁵Université de Montréal, Montreal, QC, Canada. ⁶University of Alberta, Edmonton, AB, Canada. ⁷University of British Columbia, Vancouver, BC, Canada. ⁸University of Calgary, Calgary, AB, Canada. ⁹University of Manitoba, Winnipeg, MB, Canada. ¹⁰University of Ottawa, Ottawa, ON, Canada.

Published: 13 July 2012

doi:10.1186/1546-0096-10-S1-A75

Cite this article as: Lang *et al.*: Incident vertebral fractures 12 months following glucocorticoid initiation in children with rheumatic disorders. *Pediatric Rheumatology* 2012 **10**(Suppl 1):A75.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

